---

American pharmaceutical firm AbbVie and immunotherapy platform company EvolveImmune Therapeutics have announced a partnership and option-to-license deal to develop biologics for multiple targets in cancer therapy.

The partnership will harness EvolveImmune’s T-cell engager platform to create novel antibody-based therapies targeting a range of cancers.

Together, they aim to advance multifunctional biotherapeutics designed to counteract cancer-induced immunodeficiency and tackle the issue of cancer cell resistance to existing immunotherapies.

To enhance and maintain the T-cells' ability to fight tumors, EvolveImmune's EVOLVE platform is designed to provide strong, targeted, and integrated T-cell co-stimulation.

This strategy seeks to address treatment problems in solid and hematologic cancers by reducing T-cell dysfunction, conditionally activating adaptive immunity, and avoiding low tumor immunogenicity.

---

READ ALSO: Bayer and Liveo Research unveil innovative, eco-friendly blister packaging solution

---

"We believe that EVOLVE, with its differentiated CD2 co-stimulation strategy, represents a potential next-generation, best-in-class T-cell engager platform and that our technology may offer clinically meaningful benefits for patients," Stephen Bloch, M.D., CEO, EvolveImmune.

In the deal, EvolveImmune will get $65 million in upfront fees and equity investment by AbbVie and may receive up to $1.4 billion in aggregate option fees and milestones, as well as tiered royalty payments on net sales.

AbbVie’s global head of discovery research, Jonathon Sedgwick, expressed the company's excitement at the prospect of working with the immuno-oncology firm to further develop the T-cell engager platform.

“AbbVie is dedicated to advancing the understanding of devastating diseases like cancer and investing in groundbreaking technologies and therapeutic platforms to deliver novel treatments for patients with high unmet needs," he added.

Both companies expect first-in-human clinical trials from the cancer biotherapies are anticipated in 2025.

---

Did you find this informative? Subscribe for more.

---